CervoMed to Participate in September Investor Conferences

CervoMed schedules September 2026 fireside chat and presentation at two virtual investor conferences with webcast access.

Rhea-AI Summary

CervoMed (CRVO) will participate in two investor conferences in September 2026.

Management plans a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference on Friday, September 11, 2026, from 10:55 to 11:25 AM ET. The company will also give a presentation and hold 1x1 meetings at the H.C. Wainwright Global Investment Conference on Tuesday, September 15, 2026, from 4:00 to 4:30 PM ET, both with live webcasts available.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:

Cantor Global Healthcare Conference
Format: Fireside Chat & 1x1 Investor Meetings
Date: Friday, September 11, 2026
Time: 10:55 – 11:25 AM ET

Webcast Link:
https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1

H.C. Wainwright Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Date: Tuesday, September 15, 2026
Time: 4:00 – 4:30 PM ET

Webcast Link: 
https://journey.ct.events/view/9a19abdb-8a2c-4742-bae3-a2dbdb363f7f

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Contacts:

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

FAQ

How can investors access CervoMed’s Cantor Global Healthcare Conference session?

The Cantor Global Healthcare Conference fireside chat and 1x1 meetings on September 11, 2026, from 10:55 to 11:25 AM ET can be accessed via webcast at: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1.

How can investors watch CervoMed’s presentation at the H.C. Wainwright Global Investment Conference?

The H.C. Wainwright Global Investment Conference presentation and 1x1 meetings on September 15, 2026, from 4:00 to 4:30 PM ET are available via webcast at: https://journey.ct.events/view/9a19abdb-8a2c-4742-bae3-a2dbdb363f7f.